Alonso et al. showed in a lung cancer mouse model that anti-PD-1 therapy increases the number of circulating Tfh and therefore additionally increases the number of TLS, leading to impaired tumour growth and support Tfh-associated antibody production [124]. The gene discussed is PDCD1; the disease is neoplasm.